Clinical Trial Detail

NCT ID NCT01633060
Title A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Recruitment Terminated
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant

Fulvestrant + BKM120

Age Groups: adult

Additional content available in CKB BOOST